Shares of biotechnology company Moderna (NASDAQ:MRNA) are rising today on a slew of developments. Merck (NYSE:MRK) has exercised the option to develop and bring to market Moderna’s personalized cancer vaccine under joint development. The candidate is presently being studied in combination with Keytruda for the treatment of melanoma. Importantly, Moderna will receive $250 million from Merck on exercising this option. Separately, Moderna has exercised the option for licensing Autolus Therapeutics’ (NASDAQ:AUTL) binders for an undisclosed target.
https://www.tipranks.com/news/moderna-rises-on-major-developments?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Moderna Charts.